EGFR and glioblastoma: The extracellular domain-mutated EGFR VIII found in glioblastoma is not effectively targeted by the ATP-site competitive inhibitors, potentially owing to other receptor tyrosine kinases (RTKs) such as MET (mesenchymal-epithelial transition factor) and PI3K bypassing the requirement of EGFR catalytic activity [62].